Literature DB >> 1694224

Human protectin (CD59), an 18-20-kD homologous complement restriction factor, does not restrict perforin-mediated lysis.

S Meri1, B P Morgan, M Wing, J Jones, A Davies, E Podack, P J Lachmann.   

Abstract

Human protectin (CD59) is an 18-20-kD membrane glycoprotein that restricts lysis of human erythrocytes and leukocytes by homologous complement. By directly incorporating protectin into membranes of heterologous cells we observed that protectin did not prevent perforin-mediated killing, whereas complement killing was effectively restricted. Further, no significant enhancement of cell-mediated killing or target killing by purified perforin was observed with anti-protectin antibodies. Thus, in contrast with complement lysis, restriction of lysis by protectin does not apply to cell-mediated killing.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1694224      PMCID: PMC2188136          DOI: 10.1084/jem.172.1.367

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  12 in total

1.  Structural/functional similarity between proteins involved in complement- and cytotoxic T-lymphocyte-mediated cytolysis.

Authors:  J Tschopp; D Masson; K K Stanley
Journal:  Nature       Date:  1986 Aug 28-Sep 3       Impact factor: 49.962

2.  Reversible cell damage by T-cell perforins. Calcium influx and propidium iodide uptake into K562 cells in the absence of lysis.

Authors:  J Jones; M B Hallett; B P Morgan
Journal:  Biochem J       Date:  1990-04-15       Impact factor: 3.857

3.  Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement transmembrane channels.

Authors:  Y Sugita; Y Nakano; M Tomita
Journal:  J Biochem       Date:  1988-10       Impact factor: 3.387

4.  Absence of homologous restriction factor does not affect CTL-mediated cytolysis.

Authors:  O P Krähenbühl; H H Peter; J Tschopp
Journal:  Eur J Immunol       Date:  1989-01       Impact factor: 5.532

5.  Phosphorylcholine acts as a Ca2+-dependent receptor molecule for lymphocyte perforin.

Authors:  J Tschopp; S Schäfer; D Masson; M C Peitsch; C Heusser
Journal:  Nature       Date:  1989-01-19       Impact factor: 49.962

6.  Distinct restriction of complement- and cell-mediated lysis.

Authors:  N Hollander; M L Shin; W F Rosse; T A Springer
Journal:  J Immunol       Date:  1989-06-01       Impact factor: 5.422

7.  Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria.

Authors:  M H Holguin; L R Fredrick; N J Bernshaw; L A Wilcox; C J Parker
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

8.  Structure and function of human perforin.

Authors:  M G Lichtenheld; K J Olsen; P Lu; D M Lowrey; A Hameed; H Hengartner; E R Podack
Journal:  Nature       Date:  1988-09-29       Impact factor: 49.962

9.  Characterization of a broadly expressed human leucocyte surface antigen MEM-43 anchored in membrane through phosphatidylinositol.

Authors:  I Stefanová; I Hilgert; H Kristofová; R Brown; M G Low; V Horejsí
Journal:  Mol Immunol       Date:  1989-02       Impact factor: 4.407

10.  A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement.

Authors:  N Okada; R Harada; T Fujita; H Okada
Journal:  Int Immunol       Date:  1989       Impact factor: 4.823

View more
  16 in total

1.  Killing of cells by perforin. Resistance to killing is not due to diminished binding of perforin to the cell membrane.

Authors:  J Jones; B P Morgan
Journal:  Biochem J       Date:  1991-11-15       Impact factor: 3.857

Review 2.  Membrane defence against complement lysis: the structure and biological properties of CD59.

Authors:  A Davies; P J Lachmann
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

3.  Streptococcus pneumoniae phosphoglycerate kinase is a novel complement inhibitor affecting the membrane attack complex formation.

Authors:  Anna M Blom; Simone Bergmann; Marcus Fulde; Kristian Riesbeck; Vaibhav Agarwal
Journal:  J Biol Chem       Date:  2014-10-03       Impact factor: 5.157

Review 4.  Complement regulation and kidney diseases: recent knowledge of the double-edged roles of complement activation in nephrology.

Authors:  Masashi Mizuno; Yasuhiro Suzuki; Yasuhiko Ito
Journal:  Clin Exp Nephrol       Date:  2017-03-24       Impact factor: 2.801

Review 5.  Role of complement and complement regulatory proteins in the complications of diabetes.

Authors:  Pamela Ghosh; Rupam Sahoo; Anand Vaidya; Michael Chorev; Jose A Halperin
Journal:  Endocr Rev       Date:  2015-04-10       Impact factor: 19.871

Review 6.  Membrane proteins that protect against complement lysis.

Authors:  B P Morgan; S Meri
Journal:  Springer Semin Immunopathol       Date:  1994

7.  Structural properties of the glycoplasmanylinositol anchor phospholipid of the complement membrane attack complex inhibitor CD59.

Authors:  W D Ratnoff; J J Knez; G M Prince; H Okada; P J Lachmann; M E Medof
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

8.  Modulation of retinoblastoma gene in normal adult hematopoiesis: peak expression and functional role in advanced erythroid differentiation.

Authors:  G L Condorelli; U Testa; M Valtieri; L Vitelli; A De Luca; T Barberi; E Montesoro; S Campisi; A Giordano; C Peschle
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

9.  Differential expression and functional role of GATA-2, NF-E2, and GATA-1 in normal adult hematopoiesis.

Authors:  C Labbaye; M Valtieri; T Barberi; E Meccia; B Masella; E Pelosi; G L Condorelli; U Testa; C Peschle
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

10.  Mesenchymal stem cells engineered to inhibit complement-mediated damage.

Authors:  Melisa A Soland; Mariana Bego; Evan Colletti; Esmail D Zanjani; Stephen St Jeor; Christopher D Porada; Graça Almeida-Porada
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.